7:30 PM - 8:30 PM EDT
Overview
Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder leading to neuromuscular dysfunction, and approximately half of the cases of this disease are associated with malignancy. As such, optimal management of LEMS requires careful coordination among a variety of disciplines and specialties in health care to prevent progression of both LEMS and the underlying cancer.
This live Virtual Tumor Board® webcast is specifically designed to meet the needs of busy clinicians who treat patients with cancer and LEMS by providing a framework for diagnosis and treatment. Following presentations on current and emerging principles for detecting and managing LEMS, the faculty will discuss a series of challenging cases to highlight key issues and solutions in the real-world setting from the perspective of different specialties in cancer care.
Benefits of Attending
- Gain insight from expert faculty on how best to screen for and diagnose LEMS
- Learn the best treatment options for patients with LEMS
- Engage thought leaders as they discuss current treatment principles for LEMS
Target Audience
This educational activity is directed toward oncologists, neurologists, neuromuscular specialists, and nurses.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Review the pathophysiology and diagnostic criteria of Lambert-Eaton myasthenic syndrome (LEMS)
- Assess efficacy and safety data from pivotal trials evaluating therapeutic options to treat patients with LEMS, including cancer-related LEMS
- Implement proactive multidisciplinary strategies to monitor and mitigate treatment-related toxicities in patients with LEMS
- Apply practice-changing evidence to clinical scenarios of patients with cancer-related LEMS
Time |
||
7:30 PM |
Welcome and Introduction |
Jared Weiss |
7:35 PM |
Understanding LEMS and Treatment Options |
Jared Weiss and Michael Pulley |
7:55 PM |
Case #1: Presentation of LEMS in the Oncology Clinic |
Jared Weiss |
8:05 PM |
Case #2: Assessment and Management of LEMS |
Michael Pulley |
8:15 PM |
Case #3: Nursing Challenges for Patients With LEMS |
Beth Sandy |
8:25 PM |
Concluding Remarks and Adjourn |

Jared Weiss, MD
Associate Professor of Medicine
Section Chief of Thoracic and Head/Neck Oncology
University of North Carolina Lineberger Comprehensive Cancer Center
Chapel Hill, NC
Disclosures: Grant/Research Support: Mirati Therapeutics, Sumitomo Dainippon Pharma, Boehringer Ingelheim, PDS Biotech, Merck, AstraZeneca, Amgen, CareFusion, G1 Therapeutics, Immunicum, Lilly; Consultant: AstraZeneca, EMD Serono, Genentech, G1 Therapeutics, Jounce Therapeutics, AbbVie, Nanobiotix, Azitra, Lilly, Blueprint Medicines, Pfizer, Saatchi, Jazz, BI, Regeneron, Genmab, BeiGene; Stock/Shareholder: Achilles Therapeutics, Nektar Therapeutics, Vesselon, Nuvalent, Lyell Immunopharma.

Michael Pulley, MD, PhD
Associate Professor
University of Florida College of Medicine Jacksonville
Director Neuromuscular Medicine and EMG Laboratory
UF Health Jacksonville Neuroscience Institute
Director UF Health Jacksonville Multidisciplinary ALS Clinic
Jacksonville, FL
Disclosures: Consultant: Catalyst Pharmaceuticals, Alexion Pharmaceuticals, Argenx, UCB/Ra, lmmunovant, CSL/Behring, BioProducts Laboratory.

Beth Sandy, MSN, CRNP
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
Hospital of the University of Pennsylvania
Philadelphia, PA
Disclosures: Speakers’ Bureau: Takeda Pharmaceutical Company, AstraZeneca, Merck & Co.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

